Why did Munoz et al exclude women "with pre-existing infections and women who do not complete the full course of the vaccine," ask six researchers with US National Cancer Institute. Is this also a sample of convenience? And why was "infection of 6 month duration or longer" used as an endpoint for showing a public health cancer benefit asks a different set of researchers, Stefanie Schenk and Jutta Halbekath from Berlin--when no "differentiation" between infection and cancer is given?
Clearly the letter writers need to do their CMEs.
1 | 2